Search
Immuneering Corp
IMRXAdd to Watchlist
4.410USD
0.0000.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
285.28MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Immuneering Corp is 8.67, ranking 77 out of 389 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 30.00 and a low of 11.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
17.000
Target Price
+285.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Immuneering Corp
IMRX
6
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Immuneering Corp's price target?
Analysts forecast that Immuneering Corp's price target is USD 14.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 11.00.
How have Immuneering CorpIMRX's recent earnings per share performed?
The market expectation was USD -0.21, while Immuneering CorpIMRX's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for Immuneering Corp?
Based on the ratings of Immuneering Corp's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
